Cardiology

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

AHN is proud to offer three highly skilled chronic total occlusion operators at Allegheny General Hospital.

Complex PAD may be treated by minimally invasive percutaneous transmural arterial bypass (PTAB) using the DETOUR System by Endologix.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Patients hospitalized for STEMI achieved similar outcomes with rivaroxaban as warfarin after three months of follow-up in the RIVAWAR trial.

In a new analysis at ACC.25, abelacimab reduced bleeding rates across the risk spectrum, with more benefits for those at higher bleeding risk.

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

Hosts discuss how recent advances in HFpEF have changed discussions surrounding how cardiologists should approach treatment sequencing.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

Ahmad Masri, MD, MS, discusses how new options change the historic approach to the treatment of newly diagnosed ATTR-CM.

Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

Ahmad Masri, MD, MS, discusses data detailing the effects of aficamten in oHCM from the FOREST-HCM OLE study at ACC.25.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.

Despite failing to achieve significance for its primary endpoint, investigators suggest the trial further demonstrates the potential of cell therapy in HFrEF.